Warning! GuruFocus detected
2 Severe warning signs
with DVL.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Alliance Pharma PLC
NAICS : 325412
ISIN : GB0031030819
Compare
Compare
Traded in other countries / regions
APH.UKDVL.Germany IPO Date
2018-07-19Description
Alliance Pharma PLC is a player in the healthcare market. The company's business includes the acquisition, marketing, and distribution of consumer healthcare and pharmaceutical products. The group operates in two segments: Consumer Healthcare brands and Prescription Medicines. The company generates the majority of its revenue from the Consumer Healthcare segment. The products of the company include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, Fazol, and others. Geographically, the company derives a majority of its revenue from Europe, the Middle East, and Africa (EMEA).
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.18 | |||||
| Equity-to-Asset | 0.56 | |||||
| Debt-to-Equity | 0.48 | |||||
| Debt-to-EBITDA | -3.68 | |||||
| Interest Coverage | 4.22 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 1.51 | |||||
| Beneish M-Score | -3.12 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 11.3 | |||||
| 3-Year EPS without NRI Growth Rate | -4.1 | |||||
| 3-Year FCF Growth Rate | -6.2 | |||||
| 3-Year Book Growth Rate | -8.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 8.15 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 5.41 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.15 | |||||
| 9-Day RSI | 56.99 | |||||
| 14-Day RSI | 61.91 | |||||
| 3-1 Month Momentum % | 36.79 | |||||
| 6-1 Month Momentum % | 52.95 | |||||
| 12-1 Month Momentum % | 63.29 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.93 | |||||
| Quick Ratio | 2.06 | |||||
| Cash Ratio | 0.61 | |||||
| Days Inventory | 131.58 | |||||
| Days Sales Outstanding | 84.38 | |||||
| Days Payable | 75.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Payout Ratio | 0.25 | |||||
| 3-Year Dividend Growth Rate | 33.9 | |||||
| 3-Year Average Share Buyback Ratio | -0.5 | |||||
| Shareholder Yield % | 5.59 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 59.42 | |||||
| Operating Margin % | 22.87 | |||||
| Net Margin % | -18.34 | |||||
| FCF Margin % | 15.86 | |||||
| ROE % | -14.04 | |||||
| ROA % | -7.59 | |||||
| ROIC % | 7.19 | |||||
| 3-Year ROIIC % | -9.96 | |||||
| ROC (Joel Greenblatt) % | -102.62 | |||||
| ROCE % | -9.75 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 12.17 | |||||
| PE Ratio without NRI | 13.35 | |||||
| Shiller PE Ratio | 24.91 | |||||
| PS Ratio | 1.9 | |||||
| PB Ratio | 1.56 | |||||
| Price-to-Free-Cash-Flow | 11.87 | |||||
| Price-to-Operating-Cash-Flow | 11.65 | |||||
| EV-to-EBIT | -11.06 | |||||
| EV-to-Forward-EBIT | 11.95 | |||||
| EV-to-EBITDA | -15.05 | |||||
| EV-to-Forward-EBITDA | 8.91 | |||||
| EV-to-Revenue | 2.36 | |||||
| EV-to-Forward-Revenue | 2.09 | |||||
| EV-to-FCF | 14.91 | |||||
| Price-to-GF-Value | 0.76 | |||||
| Price-to-Projected-FCF | 0.74 | |||||
| Price-to-Median-PS-Value | 0.67 | |||||
| Earnings Yield (Greenblatt) % | -9.04 | |||||
| FCF Yield % | 8.38 | |||||
| Forward Rate of Return (Yacktman) % | 9.14 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alliance Pharma PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 214.366 | ||
| EPS (TTM) (€) | -0.072 | ||
| Beta | 1.19 | ||
| 3-Year Sharpe Ratio | -0.2 | ||
| 3-Year Sortino Ratio | -0.25 | ||
| Volatility % | 31.86 | ||
| 14-Day RSI | 61.91 | ||
| 14-Day ATR (€) | 0.007126 | ||
| 20-Day SMA (€) | 0.7265 | ||
| 12-1 Month Momentum % | 63.29 | ||
| 52-Week Range (€) | 0.298 - 0.85 | ||
| Shares Outstanding (Mil) | 540.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alliance Pharma PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alliance Pharma PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Alliance Pharma PLC Frequently Asked Questions
What is Alliance Pharma PLC(FRA:DVL)'s stock price today?
The current price of FRA:DVL is €0.73. The 52 week high of FRA:DVL is €0.85 and 52 week low is €0.30.
When is next earnings date of Alliance Pharma PLC(FRA:DVL)?
The next earnings date of Alliance Pharma PLC(FRA:DVL) is 2025-09-30 Est..
Does Alliance Pharma PLC(FRA:DVL) pay dividends? If so, how much?
Alliance Pharma PLC(FRA:DVL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers